Previous reports demonstrated the aberrant somatic hypermutation (SHM) of proto-oncogenes PIM-1, MYC, RhoH and PAX5 as a novel mechanism of genetic lesion in diffuse large B-cell lymphoma (DLBCL). 1 The Rho family of small GTPases including Rho, Rac, and Cdc42 has been well characterized as molecular switches to transduce signals from plasma membrane to the downstream effectors. RhoH, a member of the Rho family, is specifically expressed in hematopoietic cells, especially in T and B lymphocytes, and has been reported to downregulate Rac 2 and LFA-1. 3 As RhoH is GTPase-deficient and constitutively active, GTP-bound form, 4 the activity of RhoH is directly related to the level of expression. Aberrant SHM of RhoH gene are distributed in intron 1 ( þ 300B1700) and have been reported in 46% of DLBCL, 1 11% of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), 5 11% of primary cutaneous follicular center lymphoma (PCFCL), 6 31% of primary cutaneous large B cell lymphoma, leg type (PCLBCL), 6 and 13% of hepatitis C virus (HCV) associated non Hodgkin lymphoma. 7 Although several studies reported the SHM of DLBCL and other lymphoid malignancy, the prognostic values of SHM remain elusive. Here, we have screened for SHM of RhoH gene in the lymph node samples from 100 previously untreated DLBCL cases.
These patients were diagnosed and treated at Nagoya University Hospital since 1987 to 2002, and median duration of follow-up was 1026 days. Informed consent was obtained from all patients. Samples from 12 cases of reactive lymphadenopathy were also screened for negative control. Intron 1 of RhoH gene was amplified and screened by the denaturing HPLC (DHPLC) analysis using the WAVE Maker System (Transgenomic Inc., San Jose, CA, USA) as previously described. 8 DHPLC gradients and temperatures were determined using WAVE Maker System software. When heterozygous profiles were identified by visual inspection of the chromatograms, amplified products were cloned into pGEM-T easy vector (Promega, Madison, WI, USA) and were sequenced on the DNA sequencer (310; Applied Biosystems, Foster City, CA, USA) using the BigDye terminator cycle-sequencing kit (Applied Biosystems). Statistical analyses were performed using the Fisher exact test for 2 Â 2 tables with StatView-J 5.5 software (Abacus Concepts Inc., Berkeley, CA, USA).
We found 78 mutations (76 point mutations, two insertions) unique to individual tumor DNAs in 35 of 100 DLBCL cases (35%) in RhoH gene (Table 1) . Overall, 73 out of 78 were novel SHM, and five were same mutations as reported previously. 1 They shared most of the features of the immunoglobulin variable gene-associated SHM mechanism such as single nucleotide substitution (n ¼ 76) with rare deletion/insertions (n ¼ 2) and a predominance of transitions (n ¼ 48) than transversions (n ¼ 28). 5 The number of mutations in one patient ranged from 1 to 6, and 20 patients had more than one mutation. These mutations were distributed in a region throughout the first 1.6 kb of the RhoH gene. No mutation was detected in DNA from reactive lymphadenopathy patients except for the known polymorphism T486G in 2/12 samples. 1 The absence of aberrant SHM tends to correlate with advanced stage (stages III and IV, P ¼ 0.06), although there was no statistical significance ( Table 2 ). The presence of aberrant SHM in RhoH gene impacted neither on overall survival (Figure 1a ) nor disease-free survival ( Figure 1b) (P ¼ 0.57 and 0.75, respectively). Taken together, our study demonstrated that although the 10  A775G  G798C  T1043C  C1119T   49  A548C  G859A  T1036A  C1057A  G1098T  G1102A  11  T676C  50  A563C  A591T  18  C746T  52  C999T  22  C505G  G1165A   53  C1081T   23  T523C  G1061A   58  C1057T  C1062T  28  G555C  G694A  G743A  C788G   60  A591G  A593G   29  G743T  G750A  G753A  G1012A   63  G530A   31  T412C  C598T  G1053A  G1061A   67  A721G   32  A993T  G1029C  G1084A   68  C715T  G817T  ins1077T  ins1110C  T1127C  33  G983A  T1085A   73  G743T   34  T851A  80  C544T  T590G  39  C885T  86  C443T  A512G  A587C  40  T939G  105  C521T  C695T  C850G  G1053T  G1107T  A1198T  41  C443T  C890T   106  T420C  C544T  42  G1029A  107  A1039C  45  G859A  113  T613C  A748C  46 T814A
Letters to the Editor SHM might contribute to the lymphomagenesis through regulation of RhoH gene expression, it has less impact on survival of DLBCL patients. 
